The move follows significant physician-led growth and investment in OneOncology.
Cencora, Inc. announced that it has signed a definitive agreement to acquire TPG’s equity interest in OneOncologya national platform that empowers independent oncology practices.
The move follows significant physician-led growth and investment in OneOncology.
Jeff Patton, MD, CEO of OneOncology, said, “We are pleased to advance our long-standing partnership with Cencora, who shares our commitment to supporting independent providers. Leveraging Cencora’s expertise while maintaining independence will enhance the value we bring to practices, allowing physicians to focus on providing accessible, innovative care.”
The acquisition of Cencora is positioned to accelerate OneOncology’s growth through expanded technology capabilities, clinical innovation, shared services and increased investment in specialty care. The platform’s physician-led model has attracted leading practices and enabled expansion into multiple local communities.
Bob Mauch, president and CEO of Cencora, noted that the acquisition aligns with the company’s pharmaceutical-focused strategy. “Since our initial investment, OneOncology has grown substantially. Combined with our recent acquisition of RCA, our goal is to strengthen research, clinical trial capabilities, advanced technology resources and medical leadership to deliver unique value to stakeholders,” Mauch said.
TPG, the outgoing investor, expressed confidence in the future of OneOncology under Cencora. Kendall Garrison, Partner at TPG, commented: “OneOncology has expanded its presence and integrated patient-centered practices into its national network since 2023. We are confident in the continued success of the platform with the support of Cencora.” John Schilling, co-managing partner of TPG Capital, added: “It has been a privilege to partner with Dr. Patton and the management team to improve cancer care and patient outcomes.”
Stay tuned for more such updates on Digital Health News
